Abbott Laboratories (ABT) Other Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $3.7 billion for Q4 2021.

• In Q4 2021, Other Non-Current Liabilities changed 0.03% year-over-year to $3.7 billion; the TTM figure through Dec 2021 stood at $3.7 billion (changed 0.03% YoY), while the FY2021 annual figure was $3.7 billion, changed 0.03% from the prior year.
• Other Non-Current Liabilities came in at $3.7 billion for Q4 2021 at Abbott Laboratories, roughly flat from $3.7 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 billion in Q4 2017 to a low of $3.7 billion in Q4 2020.
• Average Other Non-Current Liabilities over 5 years is $4.0 billion, with a median of $3.9 billion recorded in 2019.
• Year-over-year, Other Non-Current Liabilities advanced 6.73% in 2017 and retreated 17.94% in 2018.
• Over 5 years, Other Non-Current Liabilities stood at $4.9 billion in 2017, then dropped by 17.94% to $4.0 billion in 2018, then retreated by 1.0% to $3.9 billion in 2019, then slipped by 6.59% to $3.7 billion in 2020, then gained by 0.03% to $3.7 billion in 2021.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $3.7 billion in Q4 2021, $3.7 billion in Q4 2020, and $3.9 billion in Q4 2019.